Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
148.41
+0.60 (0.41%)
At close: Dec 4, 2025, 4:00 PM EST
148.94
+0.90 (0.61%)
Pre-market: Dec 5, 2025, 5:44 AM EST
Axsome Therapeutics Revenue
Axsome Therapeutics had revenue of $170.99M in the quarter ending September 30, 2025, with 63.22% growth. This brings the company's revenue in the last twelve months to $561.26M, up 65.83% year-over-year. In the year 2024, Axsome Therapeutics had annual revenue of $385.69M with 42.53% growth.
Revenue (ttm)
$561.26M
Revenue Growth
+65.83%
P/S Ratio
12.98
Revenue / Employee
$821,761
Employees
683
Market Cap
7.48B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 385.69M | 115.09M | 42.53% |
| Dec 31, 2023 | 270.60M | 220.56M | 440.80% |
| Dec 31, 2022 | 50.04M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
AXSM News
- 13 hours ago - Axsome Therapeutics, Inc. (AXSM) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript - Seeking Alpha
- 3 days ago - 2 Under-the-Radar Stocks to Buy Heading Into 2026 - The Motley Fool
- 15 days ago - Axsome Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 25 days ago - 2 Monster Stocks in the Making - The Motley Fool
- 4 weeks ago - Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy - GlobeNewsWire
- 4 weeks ago - Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics - GlobeNewsWire
- 4 weeks ago - Axsome: Alzheimer's Disease Agitation sNDA Adds Optionality, Not A Thesis Changer - Seeking Alpha
- 4 weeks ago - Axsome Therapeutics, Inc. (AXSM) Q3 2025 Earnings Call Transcript - Seeking Alpha